Literature DB >> 33864704

Human pluripotent stem cells: An alternative for 3D in vitro modelling of skin disease.

Preeti Khurana1,2, Nikola Kolundzic1,2, Carsten Flohr3, Dusko Ilic1,2.   

Abstract

To effectively study the skin and its pathology, various platforms have been used to date, with in vitro 3D skin models being considered the future gold standard. These models have generally been engineered from primary cell lines. However, their short life span leading to the use of various donors, imposes issues with genetic variation. Human pluripotent stem cell (hPSC)-technology holds great prospects as an alternative to the use of primary cell lines to study the pathophysiology of human skin diseases. This is due to their potential to generate an unlimited number of genetically identical skin models that closely mimic the complexity of in vivo human skin. During the past decade, researchers have therefore started to use human embryonic and induced pluripotent stem cells (hESC/iPSC) to derive skin resident-like cells and components. These have subsequently been used to engineer hPSC-derived 3D skin models. In this review, we focus on the advantages, recent developments, and future perspectives in using hPSCs as an alternative cell source for modelling human skin diseases in vitro.
© 2021 The Authors. Experimental Dermatology published by John Wiley & Sons Ltd.

Entities:  

Keywords:  3D skin; differentiation; human model; keratinocytes; stem cells

Mesh:

Year:  2021        PMID: 33864704     DOI: 10.1111/exd.14358

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  2 in total

1.  Epidermal Basement Membrane Substitutes for Bioengineering of Human Epidermal Equivalents.

Authors:  Nikola Kolundzic; Preeti Khurana; Debra Crumrine; Anna Celli; Theodora M Mauro; Dusko Ilic
Journal:  JID Innov       Date:  2021-12-07

Review 2.  Skin-on-a-Chip Technology: Microengineering Physiologically Relevant In Vitro Skin Models.

Authors:  Patrícia Zoio; Abel Oliva
Journal:  Pharmaceutics       Date:  2022-03-21       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.